AiCuris' Pritelivir Demonstrates Superior Efficacy in Phase 3 Trial for Drug-Resistant HSV Infections
核心洞察
AiCuris Anti-infective Cures AG announced that pritelivir met its primary endpoint in the pivotal Phase 3 PRIOH-1 trial, demonstrating statistically significant superiority in lesion healing compared to standard-of-care treatments for immunocompromised patients with acyclovir-refractory HSV infections (搜索).
The novel helicase-primase inhibitor showed superior efficacy for treatment up to 28 days (p=0.0047) and even stronger results extending to 42 days (p<0.0001), addressing a critical unmet need in patients with drug-resistant HSV strains.
Pritelivir represents a potential breakthrough as the first new HSV therapy in decades that is active against resistant strains, with AiCuris expecting to file for FDA marketing authorization in 2026.
AiCuris Anti-infective Cures AG has achieved a significant milestone in the treatment of drug-resistant herpes simplex virus (搜索) (HSV) infections, with its investigational therapy pritelivir meeting the primary endpoint in a pivotal Phase 3 clinical trial. The company announced that detailed results from the PRIOH-1 trial will be presented as a late-breaking oral presentation at the Tandem Meetings 2026, held February 4-7 in Salt Lake City, Utah.
Novel Mechanism Addresses Treatment-Resistant Infections
Pritelivir represents a fundamentally different approach to HSV treatment as a novel oral helicase-primase inhibitor that targets both HSV-1 (搜索) and HSV-2 (搜索). Unlike traditional nucleoside analogs such as acyclovir or valacyclovir, pritelivir blocks viral DNA synthesis by inhibiting the helicase-primase complex (搜索), offering a distinct mechanism of action that makes it effective against strains resistant to current standard therapies.
This unique mode of action addresses a critical unmet medical need, particularly in immunocompromised patients where resistant or refractory HSV infections can lead to severe complications and limited treatment options. The drug has held FDA Breakthrough Therapy designation for this indication since 2020, recognizing its potential to address significant unmet medical needs.
Phase 3 Trial Results Show Statistical Superiority
The PRIOH-1 trial focused specifically on immunocompromised individuals with acyclovir-refractory and sometimes foscarnet-resistant mucocutaneous HSV infections (搜索). In October 2025, AiCuris announced that pritelivir demonstrated statistically significant superiority in lesion healing compared to the investigator's choice of standard-of-care treatments, which included foscarnet, cidofovir, or topical options.
The trial results showed superiority for treatment up to 28 days with a p-value of 0.0047, and even stronger results extending to 42 days with p<0.0001. These findings represent a significant advancement for a patient population with severely limited therapeutic options.
Clinical Development and Regulatory Timeline
Earlier Phase 2 data supported a favorable safety profile for pritelivir, and clinical trials in both immunocompetent and immunocompromised individuals showed early signals of clinical efficacy compared to standard of care treatments like valacyclovir and foscarnet. Based on these promising results, AiCuris expects to file for FDA marketing authorization in 2026.
The detailed presentation will be delivered by Dr. Genovefa Papanicolaou from Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College on February 7, 2026, with full abstracts becoming available on February 4, 2026, via the conference website.
Addressing a Significant Medical Challenge
Currently, the FDA states that there is no cure for HSV infections, and no vaccine has been approved for HSV prevention as of February 2026. While antiviral medications can help shorten the duration of herpes outbreaks, treatment options remain limited, especially for immunocompromised patients who face increased severity and resistance challenges.
HSV-1 (搜索) and HSV-2 (搜索) infections cause oral and genital herpes in millions of people annually, with immunocompromised patients facing particular risks where an otherwise manageable infection can become life-threatening. Pritelivir potentially offers the first new HSV therapy in decades that demonstrates activity against resistant strains, representing a significant advancement in managing HSV complications in high-risk patient populations.